Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B.
The most important mutation associated with Multiple Endocrine Neoplasia type 2B (MEN 2B) is the change of thymine to cytosine in codon 918 of exon 16 in the RET oncogene (ATG → ACG). The aim of this work was to develop a single oligoarray by using tandem hybridization to detect the T918C/RET mutation for MEN 2B patients. Two genetically non-related families were studied; each family had a member affected by MEN2B. Both patients presented the T918C/RET mutation in a heterozygous fashion. None of the relatives was positive for this mutation; thus, these cases arose de novo. The proper mutation was confirmed by with different tools, PCR-Fok I endonuclease, direct sequencing, and also using our oligoarray. In this case, it is suitable to use a DNA target smaller than 150 bases with single- or double-stranded DNA and short probes of 7-mer. It was also possible to detect the mutation by employing different sources of DNA, fresh or paraffin-embedded tissues. Therefore, the present oligoarray can identify the most common M918T mutation of RET oncogene from a variety of DNA sources with good specificity and be a good alternative in the molecular diagnosis for MEN 2B cases.
Laboratorio de Diagnóstico Molecular, ENCB IPN, México city, México.
R A
RA
Pacheco-Rivera
E
E
Hernández-Zamora
B
B
González-Yebra
K
K
Beattie
R
R
Maldonado-Rodríguez
J C
JC
Santiago-Hernández
M E
ME
Medrano-Ortiz de Zárate
M
M
Salcedo
D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D018814:Multiple Endocrine Neoplasia Type 2b / Q000175:diagnosis* / Q000235:genetics; D020125:Mutation, Missense; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D012680:Sensitivity and Specificity
D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human
Med Sci Monit. 2000 Jul-Aug;6(4):796-800
11208413
J Intern Med. 1995 Oct;238(4):319-25
7595167
J Clin Endocrinol Metab. 1995 Jul;80(7):1989-95
7608246
Eur J Endocrinol. 2009 May;160(5):807-13
19240193
J Exp Clin Cancer Res. 1998 Jun;17(2):149-52
9700574
Expert Rev Anticancer Ther. 2008 Apr;8(4):625-32
18402529
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4913-8
8643503
Thyroid. 2009 Jun;19(6):565-612
19469690
Nat Genet. 1999 Jan;21(1 Suppl):48-50
9915501
Arch Med Res. 2003 Jan-Feb;34(1):41-9
12604374
BMC Biotechnol. 2005 Feb 15;5:8
15713227
Oncogene. 1995 Jun 15;10(12):2415-9
7784092
Orphanet J Rare Dis. 2006 Nov 14;1:45
17105651
Nat Genet. 1999 Jan;21(1 Suppl):33-7
9915498
Mol Biotechnol. 2003 Oct;25(2):113-29
14526122
Mol Biotechnol. 1999 Feb;11(1):13-25
10367279
Recent Results Cancer Res. 1998;154:229-36
10027003
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1083-91
17877642
J Intern Med. 1995 Oct;238(4):343-6
7595170
Hormones (Athens). 2009 Jan-Mar;8(1):23-8
19269918
Nat Biotechnol. 1999 Nov;17(11):1134-6
10545926
Clin Chem. 1997 Mar;43(3):453-7
9068588
Hum Genet. 1995 Apr;95(4):403-6
7705835
Hum Mutat. 1997;9(2):97-109
9067749
Clin Cancer Res. 2002 Feb;8(2):457-63
11839664